Plus, CLSN has Fast Track Designation from the FDA, Special Protocol Assessment by the FDA, and Priority Trial designation from NIH. If these results are good, they're going to beat DCTH to approval by June. Even if DCTH gets approval in June, it's a ridiculously expensive procedure for a super rare form of metastatic ocular melanoma. They'll end up with like 42 patients a year. CLSN is already in Phase II for recurrent chest wall breast cancer and colorectal liver metastases. CLSN is going after primary liver cancer, colorectal liver mets, and breast cancer. DCTH gets liver mets from ocular melanoma? You guys are missing the boat.